Bendroflumethiazide 2.5mg tablets

국가: 영국

언어: 영어

출처: MHRA (Medicines & Healthcare Products Regulatory Agency)

유효 성분:

Bendroflumethiazide

제공처:

Sovereign Medical Ltd

ATC 코드:

C03AA01

INN (국제 이름):

Bendroflumethiazide

복용량:

2.5mg

약제 형태:

Oral tablet

관리 경로:

Oral

수업:

No Controlled Drug Status

처방전 유형:

Valid as a prescribable product

제품 요약:

BNF: 02020100

환자 정보 전단

PACKAGE LEAFLET: INFORMATION FOR THE USER
BENDROFLUMETHIAZIDE 2.5 MG TABLETS BP
BENDROFLUMETHIAZIDE 5 MG TABLETS BP
bendroflumethiazide
Read all of this leaflet carefully before you start taking this
medicine because it
contains important information for you.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It
may harm them, even if their signs of illness are the same as yours.
•
If any of the side effects, talk to your doctor or pharmacist. This
includes any
possible side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. What Bendroflumethiazide Tablets are and what they are used for
2. What you need to know before you take Bendroflumethiazide Tablets
3. How to take Bendroflumethiazide Tablets
4. Possible side effects
5. How to store Bendroflumethiazide Tablets
6. Contents of the pack and other information 1. WHAT BENDROFLUMETHIAZIDE TABLETS ARE AND WHAT THEY ARE USED FOR
Bendroflumethiazide Tablets contain bendroflumethiazide as the
active
ingredient. They belong to a group of medicines called thiazide
diuretics (water
tablets). They may be used to:
•
reduce fluid retention (oedema) particularly in the heart, kidneys,
liver or that
caused by medication, by increasing the flow of urine
•
reduce high blood pressure alone or with other medication.
•
stop the production of breast milk. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE BENDROFLUMETHIAZIDE TABLETS
DO NOT TAKE BENDROFLUMETHIAZIDE TABLETS IF YOU:
•
are allergic to bendroflumethiazide, thiazides or any of the other
ingredients of
this
medicine (listed in section 6)
•
have severely impaired kidney or liver function
•
have high level of calcium in your blood (hypercalcaemia)
•
have low levels of sodium in your blood (hyponatraemia)
•
have low levels of potassium in your blood which has not responded to
treatment (refractory hypokalaemia)
•
have had

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Bendroflumethiazide 2.5mg Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Bendroflumethiazide 2.5mg
For the full list of excipients, see section 6.1
Each tablet contains 49.85mg of lactose.
3
PHARMACEUTICAL FORM
White, circular flat tablets with bevelled edges, having a CP logo on
one side and B
2.5 separated by a breakline on the reverse
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Bendroflumethiazide is indicated for:
Cases where the reduction of fluid retention by diuresis is required;
oedema of cardiac, renal or hepatic origin and iatrogenic oedema.
Bendroflumethiazide produces a moderate but usefully prolonged fall of
blood pressure in hypertensive patients. It may be used as the sole
antihypertensive agent or as an adjunct to other drugs whose action it
potentiates. In non-oedematous patients, there may be little
noticeable
diuretic effect.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
It is recommended that the tablets should be taken in the morning to
avoid nocturia.
_ Adults and children aged 12 years and over:_
Oedema: 5-10mg daily in the morning initially. Maintenance: usually
2.5mg-5mg on
only two or three days in the week. A single dose may be sufficient.
Essential Hypertension: 2.5mg in the morning. Doses above 2.5mg are
rarely necessary.
Bendroflumethiazide is used concurrently with other specific
hypotensive agents,
the dosage of such agents should be reduced and then adjusted as
necessary.
Pre-menstrual syndrome: 2.5mg each morning for seven days before the
period is due.
_Elderly _
Particular caution is needed in the elderly because of their
susceptibility to
electrolyte imbalance. Lower initial doses should be used and
electrolyte
balance and renal function should be carefully monitored.
_ Children under 12 years: _
_ _
_ _
Oedema: Up to 400µg per kg body weight daily initially, reducing to
50-100µg per kg
for maintenance. A more appropriate dosage form may be required. METHOD OF ADMINISTRATION: Oral.
4.3
CONTRAI